RE:RE:RE:RE:RE:Management delays"...back down to where they like it?"
Depends who "they" are. It might not be certain shareholders or management here, rather it's just the intended consequences of an oligopoly.
A big part of the big pharma game is the control of funding to potential competitors be that through regulatory expense hurdles, patient recruiting controls, investment banker cooperation, and the big one: all-media saturation.
I doubt very much that Goldstein wanted the awful financings that he completed despite displaying fealty to the club.
The empire no longer has any use for education, infrastructure or health, things that won't pay off in the next forecasted 4 qtrs.